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1. INTRODUCTION {#dom13508-sec-0005}
===============

The effects of glucose‐lowering medications (GLM) on cardiovascular and renal outcomes have become a major issue influencing therapeutic choices for type 2 diabetes (T2D).[1](#dom13508-bib-0001){ref-type="ref"} Regulatory agencies require that, in addition to lowering blood glucose, diabetes medications have a safe cardiovascular profile. During the last 3 years, a few new GLM have proved capable of protecting patients with T2D and high cardiovascular risk from major adverse cardiovascular events (MACE). Among these, the sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) empagliflozin and canagliflozin,[2](#dom13508-bib-0002){ref-type="ref"}, [3](#dom13508-bib-0003){ref-type="ref"} as well as the glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) liraglutide and semaglutide[4](#dom13508-bib-0004){ref-type="ref"}, [5](#dom13508-bib-0005){ref-type="ref"} reduced the risk of MACE (cardiovascular death, non‐fatal myocardial infarction or stroke). Strikingly, these drugs also showed evidence of renal protection, by reducing albuminuria and/or slowing the progression of chronic kidney disease (CKD).[2](#dom13508-bib-0002){ref-type="ref"}, [4](#dom13508-bib-0004){ref-type="ref"}, [6](#dom13508-bib-0006){ref-type="ref"}, [7](#dom13508-bib-0007){ref-type="ref"}

In phase III randomized controlled trials (RCTs), treatment with SGLT2i reduced albumin excretion rate (AER),[8](#dom13508-bib-0008){ref-type="ref"} and slowed the decline in estimated glomerular filtration rate (eGFR) over time.[9](#dom13508-bib-0009){ref-type="ref"} The mechanisms mediating such effects likely result from modulation of the tubular‐glomerular feedback[8](#dom13508-bib-0008){ref-type="ref"} and are independent from background therapy with angiotensin converting enzyme (ACE) inhibitors.[10](#dom13508-bib-0010){ref-type="ref"}

CKD is highly prevalent in T2D and is a strong accelerator of cardiovascular risk.[11](#dom13508-bib-0011){ref-type="ref"} In the longitudinal Italian Renal Insufficiency and Cardiovascular Events (RIACE) study, higher AER and lower eGFR, even in the normal range, identified individuals with increased mortality.[12](#dom13508-bib-0012){ref-type="ref"} Other observational studies and meta‐analyses show that an excess cardiovascular morbidity and mortality is linked to impaired renal function.[13](#dom13508-bib-0013){ref-type="ref"}, [14](#dom13508-bib-0014){ref-type="ref"} Therefore, it has been hypothesized that kidney protection contributes to cardiovascular protection in patients treated with SGLT2i.[15](#dom13508-bib-0015){ref-type="ref"}, [16](#dom13508-bib-0016){ref-type="ref"}

However, data from RCTs may suffer from a limited external transferability and their findings need to be reproduced in clinical practice.[17](#dom13508-bib-0017){ref-type="ref"} So‐called "real‐world studies" use data accumulated during routine clinical practice to challenge results obtained in RCTs, address broader patient populations, and find predictors of clinical response.[18](#dom13508-bib-0018){ref-type="ref"} In the present study, we retrospectively analysed the effectiveness of the SGLT2i dapagliflozin on renal endpoints (AER and eGFR) in an Italian clinical care setting.

2. METHODS {#dom13508-sec-0006}
==========

2.1. Study design and aims {#dom13508-sec-0007}
--------------------------

The DApagliflozin Real World evIdeNce in Type 2 Diabetes (DARWIN‐T2D) was a retrospective multicentre study performed at 46 diabetic specialist outpatient clinics in Italy. Details of the rationale and design of the study have been published previously.[19](#dom13508-bib-0019){ref-type="ref"} Briefly, the study aimed to describe the baseline clinical characteristics of patients who received a new prescription of dapagliflozin, a dipeptidyl peptidase‐4 (DPP‐4) inhibitor, a long‐acting GLP‐1RA (liraglutide or once‐weekly exenatide), or gliclazide in Italian routine clinical practice, and to retrospectively evaluate the change in effectiveness parameters at the first available follow‐up after 3‐12 months. An automatic software program extracted data from the same electronic chart system at all centres. The following data were collected: demographics, anthropometrics, diabetes duration, blood pressure, smoking status, fasting plasma glucose, HbA1c, lipid profile, liver enzymes, AER, eGFR (CKD‐EPI), history of complications, concomitant and previous GLM. AER values reported in charts as mg/l or mg/min (normal value 0‐20) were multiplied by 1.5 to convert to mg/g creatinine or mg/24 h equivalent (normal value 0‐30), assuming a standard urinary volume of 1500 mL.

The primary results of the study have been published previously[20](#dom13508-bib-0020){ref-type="ref"}: although dapagliflozin was initially channelled to difficult‐to‐treat patients, it provided significant benefits with regard to the control of glucose, body weight, and blood pressure that were in line with findings from RCTs. Owing to the massive channelling bias, it was not possible to perform a propensity score matched comparison between the groups of patients who initiated dapagliflozin and those who initiated comparators.

In the present sub‐analysis of the DARWIN‐T2D study, we aimed to evaluate the effects of dapagliflozin on renal endpoints (the change from baseline in AER and eGFR) and to compare them with the effects of other GLM (combined GLP‐1RA, DPP‐4 inhibitors, or gliclazide).

2.2. Patient selection {#dom13508-sec-0008}
----------------------

Because the primary study aim was to describe the baseline clinical characteristics of patients who received dapagliflozin in clinical practice, the follow‐up visit was available for only a fraction of patients. We anticipated that data on AER and eGFR would only be available at both visits for some of the patients with a follow‐up visit because the guidelines do not necessarily recommend checking renal function at short intervals in all patients. We thus identified patients for whom AER was available at both visits, those for whom eGFR was available at both visits, and those for whom both AER and eGFR were available at both visits. We calculated the change in AER and eGFR as the difference from baseline to follow‐up. We also calculated the changes in HbA1c, body weight and blood pressure in the subgroup of patients with available data for AER and/or eGFR at both visits.

2.3. Statistical analysis {#dom13508-sec-0009}
-------------------------

Normality of continuous variables was tested with the Kolmogorov‐Smirnov test. Non‐normal variables were log‐transformed before statistical analysis. Normal variables are presented as mean ± standard deviation, whereas non‐normal variables are given as median (interquartile range \[IQR\]). Categorical variables are summarized using percentages. Differences between the two groups of patients who received dapagliflozin or comparator GLM were analysed using the unpaired Student\'s t test for continuous variables or the chi‐squared test for categorical variables. Owing to the large number of comparisons, the Bonferroni correction was used to adjust for alpha inflation because of multiple testing. Significance of the change from baseline in AER and eGFR was tested using the paired Student\'s t test or, if necessary, the Wilcoxon rank test. We also calculated the percentage of patients in the various categories of AER (normo‐, micro‐, macro‐albuminuria) at baseline and at follow‐up. The significance of moving along AER categories was tested using the Wilcoxon rank test. A multiple regression analysis was used to adjust the effects of dapagliflozin versus those of comparator GLM on renal endpoints. Covariates were selected as those being significantly different between the two groups after Bonferroni correction. Variables with missing data were handled with a multiple imputation (MI) procedure using the Monte Carlo Markov Chain (MCMC) method and *n* = 20 imputations. The Pearson\'s r coefficient was used to test linear correlations between the change in AER (log‐transformed) or eGFR and clinical characteristics, as well as the change in other effectiveness variables. In addition, to detect clinical response patterns, we used random forests (RF) and partial least squares (PLS) algorithms with change in AER (log‐transformed) as the dependent variable (see the File [S1](#dom13508-supitem-0001){ref-type="supplementary-material"} for this article for further details). The statistical significance level was set at 0.05. SPSS ver. 23 and R ver. 3.5.0 were used.

3. RESULTS {#dom13508-sec-0010}
==========

3.1. Characteristics of study patients {#dom13508-sec-0011}
--------------------------------------

Of the 2484 patients identified at baseline and who started dapagliflozin, 830 had an available follow‐up visit during the observation period. Of these, 497 (60.0%) had at least one renal endpoint available both at the baseline and follow‐up visits; *n* = 273 patients had valid AER data at both visits, n = 393 patients had valid eGFR values at both visits, and *n* = 169 patients had both endpoints available at both visits. Of the 14 801 patients in the comparator group who were evaluated at baseline, 5921 had a follow‐up visit and 2973 (50.2%) had AER and/or eGFR available at both visits (*n* = 2277 for eGFR, *n* = 1380 for AER, *n* = 684 for both) (Figure [1](#dom13508-fig-0001){ref-type="fig"}).

![Study flowchart. T2D, type 2 diabetes; AER, albumin excretion rate; eGFR, estimated glomerular filtration rate](DOM-21-252-g002){#dom13508-fig-0001}

Clinical characteristics of the two groups are compared in Table [1](#dom13508-tbl-0001){ref-type="table"}: variables that remained significantly different after Bonferroni correction were age, BMI, diastolic blood pressure, fasting plasma glucose, baseline HbA1c, triglycerides, concomitant use of metformin, insulin, and diuretics, and prevalence of microangiopathy. Extended data are available in Table [S1](#dom13508-supitem-0001){ref-type="supplementary-material"} (see the File [S1](#dom13508-supitem-0001){ref-type="supplementary-material"} for this article).

###### 

Comparison of baseline characteristics between the two groups

                             Dapagliflozin (*n* = 497)   Comparators (*n* = 2973)                          
  -------------------------- --------------------------- -------------------------- ------- -------------- ------------------------------------------------
  Age, y                     100.0                       60.5 ± 9.3                 100.0   67.3 ± 9.0     \<0.001[a](#dom13508-note-0005){ref-type="fn"}
  Sex: Male, %               100.0                       61.0                       100.0   59.8           0.625
  Current smoking, %         22.3                        23.4                       22.3    20.1           0.426
  Diabetes duration, y       100.0                       12.5 ± 8.4                 99.9    11.6 ± 7.8     0.012
  BMI, kg/m^2^               93.2                        32.8 ± 5.8                 91.3    29.9 ± 5.3     \<0.001[a](#dom13508-note-0005){ref-type="fn"}
  SBP, mm Hg                 73.8                        139.6 ± 18.3               78.3    137.8 ± 18.7   0.087
  DBP, mm Hg                 73.6                        81.2 ± 10.3                78.2    78.7 ± 9.0     \<0.001[a](#dom13508-note-0005){ref-type="fn"}
  FPG, mg/dL                 92.8                        173.9 ± 52.3               91.2    157.1 ± 38.3   \<0.001[a](#dom13508-note-0005){ref-type="fn"}
  HbA1c, %                   99.0                        8.6 ± 1.3                  98.8    7.9 ± 1.0      \<0.001[a](#dom13508-note-0005){ref-type="fn"}
  Total cholesterol, mg/dL   79.5                        174.4 ± 40.6               79.3    170.1 ± 37.2   0.038
  HDL cholesterol, mg/dL     77.9                        46.5 ± 13.5                76.8    48.0 ± 13.5    0.035
  Triglycerides, mg/dL       79.9                        166.3 ± 133.3              78.1    147.0 ± 90.3   \<0.001[a](#dom13508-note-0005){ref-type="fn"}
  LDL cholesterol, mg/dL     73.4                        95.8 ± 32.1                75.0    92.9 ± 31.3    0.104
  SGOT, U/L                  48.1                        25.9 ± 20.1                48.6    23.0 ± 12.8    0.003
  SGPT, U/L                  53.1                        33.0 ± 20.2                49.7    27.3 ± 17.6    \<0.001[a](#dom13508-note-0005){ref-type="fn"}
  eGFR, ml/min/1.73 m^2^     83.1                        87.8 ± 16.4                82.5    79.5 ± 18.7    \<0.001[a](#dom13508-note-0005){ref-type="fn"}
  AER, mg/g                  63.2                        104.9 ± 342.7              58.6    76.2 ± 261.3   0.089
  Associated GLM                                                                                           
  Insulin                    99.8                        55.4                       100.0   15.2           \<0.001[a](#dom13508-note-0005){ref-type="fn"}
  Metformin                  99.8                        99.2                       100.0   79.7           \<0.001[a](#dom13508-note-0005){ref-type="fn"}
  Other medications                                                                                        
  Antiplatelet               87.3                        48.6                       86.7    54.6           0.022
  Statin                     87.3                        65.0                       98.4    59.2           0.023
  ACEi/ARBs                  87.3                        72.6                       86.7    71.3           0.577
  CCB                        87.3                        25.1                       98.4    20.1           0.016
  Betablockers               87.3                        31.6                       98.4    26.7           0.032
  Diuretics                  87.3                        9.7                        86.7    23.2           \<0.001[a](#dom13508-note-0005){ref-type="fn"}
  Complications                                                                                            
  Microangiopathy            100.0                       41.9                       93.2    32.6           \<0.001[a](#dom13508-note-0005){ref-type="fn"}
  Macroangiopathy            86.5                        32.8                       83.3    36.8           0.115

Data are expressed as mean ± standard deviation, or as % where appropriate. Per cent of available data is reported for all variables.

Abbreviations: ACEi, angiotensin‐converting enzyme inhibitors; AER, albumin excretion rate; ARBs, angiotensin receptor blockers; BMI, body mass index; CCB, calcium channel blockers; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; GLM, glucose‐lowering medications; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; SBP, systolic blood pressure; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase.

Statistically significant after Bonferroni correction.

To evaluate selection bias, we compared the 3470 patients with and the 3281 patients without follow‐up data for renal endpoints: variables with a standardized difference \> 0.1 (indicating imbalance) were age, diabetes duration, LDL cholesterol and statin use, baseline eGFR, and microangiopathy (Table [S2](#dom13508-supitem-0001){ref-type="supplementary-material"}).

3.2. Change in renal endpoints during therapy with dapagliflozin versus comparators {#dom13508-sec-0012}
-----------------------------------------------------------------------------------

The change in AER was examined in 273 patients who received dapagliflozin and in 1380 patients who received a comparator (Table [2](#dom13508-tbl-0002){ref-type="table"}). During therapy with dapagliflozin, median (IQR) AER declined from 19.5 (7.5‐78.2) to 13.2 (6.5‐45.0) mg/g (*P* \< 0.0001), equivalent to a 37% reduction (Figure [2](#dom13508-fig-0002){ref-type="fig"}A). The average ± SEM AER change was −39.3 ± 14.8 mg/g. Significant decreases in AER occurred only in patients with micro‐ or macroalbuminuria, but not in patients with normoalbuminuria at baseline (Figure [2](#dom13508-fig-0002){ref-type="fig"}B,D).

###### 

Change in AER in the various subgroups of patients

                                    Dapagliflozin           Comparators                                                                                                                                                                                                        
  --------------------------------- ----------------------- ------------------------------------------------------------- ------------------------------------------------------------ ------------------------ -------------------------------------------------------------- ------------------------
  All patients, *n*                 273                     273                                                           273                                                          1380                     1380                                                           1380
  Mean ± SEM                        105.0 ± 20.3            65.8 ± 10.4[a](#dom13508-note-0007){ref-type="fn"}            −39.3 ± 14.8[b](#dom13508-note-0008){ref-type="fn"}          76.3 ± 6.6               70.4 ± 6.1                                                     −5.9 ± 4.1
  Median (IQR)                      19.5 (7.5; 78.1)        13.2 (6.5; 45.0)[a](#dom13508-note-0007){ref-type="fn"}       −2.1 (−26.4; 2.3)[b](#dom13508-note-0008){ref-type="fn"}     14.9 (7.2; 41.3)         12.3 (7.0; 34.4)                                               −0.5 (−9.6; 4.3)
  By baseline albuminuria                                                                                                                                                                                                                                                      
  Normoalbuminuria, *n*             164                     164                                                           164                                                          951                      951                                                            951
  Mean ± SEM                        10.5 ± 0.6              13.3 ± 1.9                                                    2.8 ± 1.8                                                    10.6 ± 0.2               14.9 ± 1.1[a](#dom13508-note-0007){ref-type="fn"}              4.3 ± 1.1
  Median (IQR)                      8.4 (5.5; 15.2)         8.8 (4.8; 13.3)                                               0.0 (−3.0; 2.7)                                              8.9 (5.1; 15.3)          8.8 (4.9; 51.3)                                                0.0 (−3.0; 3.9)
  Microalbuminuria, n               93                      93                                                            93                                                           356                      356                                                            356
  Mean ± SEM                        108.6 ± 7.0             84.7 ± 14.1                                                   −23.8 ± 13.6                                                 90.6 ± 3.4               90.1 ± 7.8                                                     −0.5 ± 6.9
  Median (IQR)                      90.0 (52.1; 143.9)      49.4 (21.6; 89.1)[a](#dom13508-note-0007){ref-type="fn"}      −35.3 (−75.9; −3.3)[b](#dom13508-note-0008){ref-type="fn"}   66.7 (42.0; 121.2)       43.5 (20.1; 93.4)                                              −17.7 (−46.7; 7.1)
  Macroalbuminuria, n               16                      16                                                            16                                                           73                       73                                                             73
  Mean ± SEM                        1054.0 ± 243.6          493.1 ± 107.2[a](#dom13508-note-0007){ref-type="fn"}          −560.9 ± 204.0[b](#dom13508-note-0008){ref-type="fn"}        861.5 ± 78.9             697.5 ± 76.4[a](#dom13508-note-0007){ref-type="fn"}            −164.0 ± 66.7
  Median (IQR)                      590.8 (480.2; 1228.5)   379.1 (172.4; 661.7)[a](#dom13508-note-0007){ref-type="fn"}   −265.4 (−786.0; −113.2)                                      630.6 (389.6; −1082.0)   519.0 (318.0; −858.0)[a](#dom13508-note-0007){ref-type="fn"}   −184.5 (−343.5; −95.0)
  By ACEi/ARBs therapy                                                                                                                                                                                                                                                         
  No ACEi/ARBs, *n*                 68                      68                                                            68                                                           345                      345                                                            345
  Mean ± SEM                        44.5 ± 9.4              24.5 ± 4.3[a](#dom13508-note-0007){ref-type="fn"}             −20.1 ± 7.4                                                  47.5 ± 10.1              32.7 ± 4.4                                                     −14.7 ± 8.0
  Median (IQR)                      11.4 (6.5; 50.1)        10.8 (6.0; 27.0)[a](#dom13508-note-0007){ref-type="fn"}       −1.5 (−8.1; 2.0)                                             10.7 (6.8; 25.9)         10.5 (6.4; 23.0)                                               −0.5 (−6.0; 3.0)
  ACEi/ARBs, *n*                    179                     179                                                           179                                                          872                      872                                                            872
  Mean ± SEM                        132.8 ± 30.2            83.5 ± 15.1[a](#dom13508-note-0007){ref-type="fn"}            −49.3 ± 22.4[b](#dom13508-note-0008){ref-type="fn"}          96.4 ± 9.6               93.2 ± 9.4                                                     −3.2 ± 5.7
  Median (IQR)                      23.7 (8.5; 103.7)       15.8 (8.1; 66.8)[a](#dom13508-note-0007){ref-type="fn"}       −3.0 (−31.9; 3.0)[b](#dom13508-note-0008){ref-type="fn"}     16.9 (7.4; 56.5)         13.4 (7.1; 45.1)                                               −0.7 (−12.4; 4.6)
  By baseline eGFR                                                                                                                                                                                                                                                             
  eGFR \>90 mL/min/1.73 m^2^, *n*   97                      97                                                            97                                                           293                      293                                                            293
  Mean ± SEM                        136.5 ± 45.5            82.8 ± 23.8                                                   −53.7 ± 33.6                                                 58.5 ± 9.1               49.6 ± 8.8                                                     −8.9 ± 8.0
  Median (IQR)                      19.0 (7.4; −75.0)       12.0 (7.5; −48.8)[a](#dom13508-note-0007){ref-type="fn"}      −2.1 (−27.0; −2.7)                                           15.2 (6.8; 47.3)         12.0 (6.0; 32.4)                                               −1.0 (−12.3; 4.5)
  eGFR ≤90 mL/min/1.73 m^2^, *n*    92                      92                                                            92                                                           566                      566                                                            566
  Mean ± SEM                        115.6 ± 34.3            69.2 ± 15.0                                                   −46.4 ± 25.6[b](#dom13508-note-0008){ref-type="fn"}          96.9 ± 12.5              94.2 ± 12.3                                                    −2.8 ± 6.8
  Median (IQR)                      25.1 (8.1; −123.7)      18.5 (7.1; −70.1)[a](#dom13508-note-0007){ref-type="fn"}      −2.7 (−30.7; −2.0)[b](#dom13508-note-0008){ref-type="fn"}    15.8 (6.5; 48.9)         13.0 (6.0; 39.2)                                               −0.7 (−10.6; 4.6)

Values of AER are reported both as mean ± SEM (with p values from paired Student\'s t test) and as median and IQR (with *P* values from Wilcoxon rank test). ACEi, angiotensin‐converting enzyme inhibitors; ARBs, angiotensin receptor blockers.

*P* \< 0.05 versus baseline.

*P* \< 0.05 versus comparators.

![Change in AER during therapy with dapagliflozin or comparators. Values of AER at baseline (pre) and at follow‐up (post), along with the change from baseline (right panel), are shown for A, all patients, B, patients with baseline normoalbuminuria, C, microalbuminuria or D, macroalbuminuria. Columns\' height in histograms indicate median value, whereas bars indicate the interquartile range. \**P* \< 0.05 for the indicated comparison](DOM-21-252-g001){#dom13508-fig-0002}

In patients who received a comparator, overall AER did not change significantly from baseline to follow‐up (average ± SEM change −5.9 ± 4.1 mg/g; *P* = 0.156), although it declined in those with baseline macroalbuminuria. The change in AER was significantly greater during therapy with dapagliflozin than with comparators, especially for patients with micro/macroalbuminuria at baseline (Table [2](#dom13508-tbl-0002){ref-type="table"}). During therapy with dapagliflozin, AER declined significantly both in patients with and in those without ongoing therapy with ACE inhibitors (ACEi) or angiotensin receptor blockers (ARBs), while AER did not change significantly in the comparator group, irrespective of therapy with ACEi/ARBs. The change from baseline in AER in patients on ACEi/ARBs was significantly greater during therapy with dapagliflozin than comparators. Dapagliflozin reduced AER irrespectively of baseline eGFR (\< or \> 90 mL/min/1.73 m^2^) and significantly more than comparators in patients with eGFR \<90 mL/min/1.73 m^2^ (Table [2](#dom13508-tbl-0002){ref-type="table"}).

After adjusting for baseline differences between the two groups with a multiple regression analysis, therapy with dapagliflozin remained associated with a significantly greater reduction in AER than therapy with comparators (−26.4 ± 13.1 mg/g; *P* = 0.045) (Table [3](#dom13508-tbl-0003){ref-type="table"}).

###### 

Results of the multiple regression analysis

  Variable                          B ± SEM          *P*
  --------------------------------- ---------------- ---------
  Dapagliflozin (vs. comparators)   −26.42 ± 13.14   0.045
  Age, y                            0.39 ± 0.57      0.497
  BMI, kg/m^2^                      0.49 ± 0.86      0.564
  Diastolic blood pressure, mm Hg   −0.36 ± 0.47     0.444
  Fasting plasma glucose, mg/dL     −0.45 ± 0.18     \<0.001
  HbA1c, %                          −4.14 ± 5.02     0.410
  Triglycerides, mg/dL              0.02 ± 0.04      0.585
  SGPT, U/L                         0.12 ± 0.24      0.618
  eGFR, mL/min/1.73 m^2^            0.33 ± 0.29      0.251
  Insulin use (yes vs. no)          −2.80 ± 11.4     0.806
  Metformin use (yes vs. no)        24.50 ± 13.27    0.065
  Diuretic use (yes vs. no)         −7.19 ± 11.16    0.520
  Microangiopathy (yes vs. no)      −17.61 ± 8.80    0.045

Change in AER was the dependent variable, whereas covariates were selected as variables that remained different between the two groups after Bonferroni correction (see Table [1](#dom13508-tbl-0001){ref-type="table"}).

According to AER categories, 12.8% of patients in the dapagliflozin group and 10.9% in the comparator group regressed to a lower AER class, whereas 4.4% in the dapagliflozin group and 8.3% in the comparator group progressed to a higher class, for a net improvement of 8.4% in the dapagliflozin group versus 2.6% in the comparator group (*P* \< 0.001) (Figure [S1](#dom13508-supitem-0001){ref-type="supplementary-material"}).

The change in eGFR was analysed in 393 patients in the dapagliflozin group and 2277 patients in the comparator group. During therapy with dapagliflozin, mean ± SD eGFR declined from 87.5 ± 16.3 to 86.5 ± 17.8 mL/min/1.73 m^2^ (*P* = 0.049), with a reduction of 1.1 mL/min/1.73 m^2^. During therapy with a comparator, eGFR declined from 79.2 ± 18.8 to 78.6 ± 19.1 mL/min/1.73 m^2^ (*P* = 0.002), equivalent to a reduction of 0.6 mL/min/1.73 m^2^. The change from baseline in eGFR between the two groups was not significantly different (*P* = 0.35). No patient in the dapagliflozin group versus 4 patients in the comparator group exhibited a doubling of serum creatinine; no patient in the dapagliflozin group versus 11 patients in the comparator group exhibited a decline of \>40% in eGFR (both not significantly different between groups).

3.3. Overall effectiveness of dapagliflozin and comparators {#dom13508-sec-0013}
-----------------------------------------------------------

Effectiveness of dapagliflozin and comparators on glucose control, blood pressure and body weight has already been described in the total cohort of patients with a follow‐up examination.[20](#dom13508-bib-0020){ref-type="ref"} In the present subgroups, HbA1c declined by 0.8 ± 1.2% in the dapagliflozin group (*n* = 490) and 0.6 ± 1.1% in the comparator group (*n* = 2899); body weight decreased by 2.9 ± 3.5 kg in the dapagliflozin group (*n* = 456) and 0.6 ± 3.3 kg in the comparator group (*n* = 2631); systolic blood pressure declined by 3.3 ± 17.5 mm Hg in the dapagliflozin group (*n* = 336) and 0.2 ± 19.4 mm Hg in the comparator group (n = 1972).

Because there was no correlation between the changes in HbA1c and systolic blood pressure (SBP) (r = 0.04; *P* = 0.100), in an exploratory analysis we selected patients who experienced a below median response in HbA1c and an above median response in SBP: in 31 patients who received dapagliflozin, AER declined by 35%, from median (IQR) 23.7 (6.7; 137.3) to 16.9 (6.8; 80.4) (*P* = 0.09), while in 162 patients who received comparators, AER tended to increase by 23% (*P* = 0.13).

3.4. Predictors of improvement in AER {#dom13508-sec-0014}
-------------------------------------

To detect predictors of AER decline in patients who received dapagliflozin, we first analysed linear correlations: the change in AER was inversely related to change in eGFR (r = −0.17; *P* = 0.024; *n* = 169), but not to the change in other efficacy variables (HbA1c, blood pressure and body weight). Thus, we used two complementary non‐linear approaches: random forests and PLS (Table [S3](#dom13508-supitem-0001){ref-type="supplementary-material"}). Variables detected by RF were, in order of importance, HDL, LDL, diastolic blood pressure, triglycerides, total cholesterol, SBP and disease duration. According to PLS, only baseline AER, HbA1c and diastolic blood pressure had a significant impact.

4. DISCUSSION {#dom13508-sec-0015}
=============

In this real‐world study, T2D patients initiating dapagliflozin experienced a significant reduction in AER at the first follow‐up visit, on average \~6 months after baseline. Remarkably, a similar effect was not observed with comparator GLM. While a mild and marginally significant decline in eGFR was observed during dapagliflozin use, there was no evidence of clinically meaningful impairment in renal function. These results are extremely consistent with findings from phase III RCTs and confirm that dapagliflozin exerts beneficial effects on the kidney. Because renal protection can contribute to cardiovascular protection, we argue that these data lend support to the potential cardiovascular efficacy of dapagliflozin. While awaiting for results of the dedicated cardiovascular outcome trial,[21](#dom13508-bib-0021){ref-type="ref"} registry studies indicate that dapagliflozin can protect from cardiovascular events similarly to other SGLT2i.[22](#dom13508-bib-0022){ref-type="ref"}

In RCTs, dapagliflozin consistently reduced AER by 36‐40%[8](#dom13508-bib-0008){ref-type="ref"}, [9](#dom13508-bib-0009){ref-type="ref"} irrespective of therapy with ACE inhibitors or ARBs.[10](#dom13508-bib-0010){ref-type="ref"} In our study, AER declined by 37% in patients taking, and by 45% in patients not taking ACEi/ARBs. The antiproteinuric effects of dapagliflozin are probably largely independent of glucose control, as patients who experienced a decline in SBP with no decline in HbA1c showed an AER reduction quantitatively similar to the entire cohort, while the same was not observed in patients taking other GLM. This observation is consistent with the supposed direct renal effect of SGLT2i via reactivation of the tubular‐glomerular feedback.[23](#dom13508-bib-0023){ref-type="ref"}

Owing to the non‐randomized nature of the comparison between treatments, the analysis of AER response predictors was performed only in the dapagliflozin group. The change in eGFR emerged as the sole linear predictor, but it explained \<3% of AER variation. Non‐linear approaches identified blood pressure, lipid profile, HbA1c and disease duration as variables that impacted the ability of dapagliflozin to lower AER. While triglycerides have already been associated with diabetic nephropathy,[24](#dom13508-bib-0024){ref-type="ref"}, [25](#dom13508-bib-0025){ref-type="ref"}, [26](#dom13508-bib-0026){ref-type="ref"} it is remarkable that cholesterol levels modulated the renal effects of SGLT2i.

In RCTs, dapagliflozin therapy was associated with an initial drop in eGFR, followed by eGFR stabilization, such that, after 2 years of treatment, eGFR was significantly higher than in placebo‐treated patients.[27](#dom13508-bib-0027){ref-type="ref"} The mild decline in eGFR we observe at \~6 months after initiation of dapagliflozin is consistent with RCTs and the change in eGFR during dapagliflozin was not significantly different than during therapy with comparators. Our data are also particularly reassuring on the risk that SGLT2i may acutely worsen renal function. Postmarketing pharmacovigilance has identified cases of acute kidney injury (AKI) in patients taking SGLT2i,[28](#dom13508-bib-0028){ref-type="ref"}, [29](#dom13508-bib-0029){ref-type="ref"} probably because of alterations of renal haemodynamics.[30](#dom13508-bib-0030){ref-type="ref"}, [31](#dom13508-bib-0031){ref-type="ref"} On the contrary, an observational study comparing 377 SGLT2i users with 377 matched non‐users did not find any association between SGLT2i and AKI.[32](#dom13508-bib-0032){ref-type="ref"} In our survey, we found no case of doubling of serum creatinine among 393 patients initiated on dapagliflozin, also suggesting that dapagliflozin did not precipitate AKI over the \~6‐month follow‐up.

Interpretation of our results must take into consideration the study\'s limitations. First, AER was derived from a single measure and had to be converted from different units of measure. This is, however, commonly carried out in clinical practice and validated in epidemiological research.[33](#dom13508-bib-0033){ref-type="ref"} Second, patients who received comparator GLM in the DARWIN‐T2D trial were significantly different to those who received dapagliflozin. As already noted, because of the massive channelling of dapagliflozin to difficult‐to‐treat patients, a propensity score matching was inefficient and adjustment was performed using multiple regression. Thus, the degree of evidence that can be inferred from this observational study is not comparable to that of an RCT. Third, follow‐up duration was short (\~6 months), only allowing an analysis of acute changes in renal endpoints. While the effects of dapagliflozin on AER are expected to be rapid,[8](#dom13508-bib-0008){ref-type="ref"} a longer observation will be needed to evaluate benefits over time and trends in eGFR. The fact that AER did not decline in the comparator group must also be interpreted in view of the short follow‐up, because GLP‐1RA and DPP‐4 inhibitors may take longer to reduce AER.[34](#dom13508-bib-0034){ref-type="ref"}, [35](#dom13508-bib-0035){ref-type="ref"} Finally, the sample size was small: less than 60% of patients had AER and/or eGFR available at both visits. This was not surprising, because eGFR and AER are not routinely checked at short intervals in all patients, but it suggests that selection bias cannot be ruled out and generalizability should be considered with caution.

In summary, this is the first real‐world study confirming that a short‐term treatment with the SGLT2i dapagliflozin reduces albuminuria and does not cause a clinically meaningful worsening in renal function. Although longer and larger studies may be needed to establish whether these benefits persist over time in the real world, our study supports the validity and importance of registry interrogation to determine transferability of RCT data to the clinical setting.
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**File S1.** Online supplement

**Table S1. Baseline clinical characteristics of study patients**. Patients are divided according to the availability of AER and/or eGFR at both visits. Percent of available data is reported for all variable. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL, high density lipoprotein; LDL low density lipoprotein; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase; AER, albumin excretion rate; eGFR, estimated glomerular filtration rate; ACEi, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CCB, calcium channel blockers; PAD, peripheral arterial disease; TIA, transient ischemic attack.

**Table S2. Analysis of selection bias**. Comparison of clinical characteristics between patients with and without data on renal outcomes at follow‐up. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL, high density lipoprotein; LDL low density lipoprotein; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase; AER, albumin excretion rate; eGFR, estimated glomerular filtration rate; ACEi, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CCB, calcium channel blockers. P‐values for the comparison between groups are shown. However, statistical significance based on p‐values largely depends on sample size and does not inform on the magnitude of the difference. Thus, to better evaluate clinical meaningfulness of the differences, we calculated the standardized difference (D). A value of D ≤ 0.10 is usually indicative of a good match between groups.

**Table S3**. **Determinants of the change in AER.** The Random Forest (RF) procedure selected variables on the basis of the percentage increment in mean square error (%IncMSE). We created decision trees and their errors for 500 bootstrapped sub‐datasets and compared them with the error obtained permuting values of each variable: the higher the %IncMSE the greater the importance of each variable (1). Partial least squares (PLS) regression, also known as projection to latent structures, is an extension of the principal component analysis, and was run to identify variables that most contributed to the change in AER. A variable importance in projection (VIP) of 0.8 or higher and with a 95% jacknifed confidence interval not crossing zero was chosen to select the variables that most affected the outcome (2). VIPs and %IncMSEs from individual imputed datasets were pooled as described by Rubin (3). Variables marked with \* are considered to be the most significant contributors to change in AER. AER, albumin excretion rate; LDL, low density lipoproteins; HDL, high density lipoproteins; TC, total cholesterol; TG, triglycerides; FPG, fasting plasma glucose; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; %IncMSE, percent increase in mean square error; VIP, variable importance in projection.

**Figure S1. Change in albuminuria category**. For patients who received dapagliflozin or comparators, we calculated the percentages of patients who exhibited a progression (+) or a regression (−) in AER category for the entire cohort (all) and by baseline albuminuria class. \**P* \< 0.05 from chi square test.
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Click here for additional data file.
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Agostino Consoli and Gloria Formoso (Dipartimento di Medicina e Scienze dell\'Invecchiamento ‐ Università Degli studi G. D\'Annunzio di Chieti‐Pescara); Giovanni Grossi (Ospedale San Francesco di Paola ‐ Azienda Sanitaria Provinciale di Cosenza); Achiropita Pucci (Azienda Sanitaria Provinciale di Cosenza); Giorgio Sesti and Francesco Andreozzi (Azienda Ospedaliero Universitaria di Catanzaro); Giuseppe Capobianco (Azienda Sanitaria Locale Napoli 2 Nord); Adriano Gatti (Ospedale San Gennaro dei Poveri ‐ Azienda Sanitaria Locale Napoli 1 Centro); Riccardo Bonadonna, Ivana Zavaroni and Alessandra Dei Cas (Azienda Ospedaliero Universitaria di Parma); Giuseppe Felace (Ospedale di Spilimbergo ‐ Azienda per l\'Assistenza Sanitaria n.5 Friuli Occidentale); Patrizia Li Volsi (Ospedale di Pordenone ‐ Azienda per l\'Assistenza Sanitaria n.5 Friuli Occidentale); Raffaella Buzzetti and Gaetano Leto (Ospedale Santa Maria Goretti ‐ Azienda Sanitaria Locale di Latina); Gian Pio Sorice (Fondazione Policlinico Universitario A. Gemelli, Roma); Paola D\'Angelo (Ospedale Sandro Pertini ‐ Azienda Sanitaria Locale Roma 2); Susanna Morano (Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma); Antonio Carlo Bossi (Ospedale di Treviglio ‐ Azienda Socio Sanitaria Territoriale Bergamo Ovest); Edoardo Duratorre (Ospedale Luini Confalonieri di Luino ‐ Azienda Socio Sanitaria Territoriale Sette Laghi); Ivano Franzetti (Ospedale Sant\'Antonio Abate di Gallarate ‐ Azienda Socio Sanitaria Territoriale Valle Olona); Paola Silvia Morpurgo (Ospedale Fatebenefratelli ‐ Azienda Socio Sanitaria Territoriale Fatebenefratelli Sacco); Emanuela Orsi (Fondazione IRCCS Ca' Granda ‐ Ospedale Maggiore Policlinico di Milano); Fabrizio Querci (Ospedale Pesenti Fenaroli di Alzano Lombardo ‐ Azienda Socio Sanitaria Territoriale Bergamo Est); Massimo Boemi† and Federica D\'Angelo (Presidio Ospedaliero di Ricerca INRCA‐IRCCS di Ancona); Massimiliano Petrelli (Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona); Gianluca Aimaretti and Ioannis Karamouzis (Azienda Ospedaliero Universitaria Maggiore della Carità di Novara); Franco Cavalot (Azienda Ospedaliero Universitaria San Luigi Gonzaga, Orbassano); Giuseppe Saglietti† (Ospedale Madonna del Popolo di Omegna ‐ Azienda Sanitaria Locale Verbano Cusio Ossola); Giuliana Cazzetta (Casa della Salute, Ugento ‐ Distretto Socio Sanitario Gagliano del Capo ‐ Azienda Sanitaria Locale di Lecce); Silvestre Cervone (Presidio ospedaliero San Marco in Lamis ‐ Distretto Socio Sanitario San Marco in Lamis ‐ Azienda Sanitaria Locale di Foggia); Eleonora Devangelio (Distretto Socio Sanitario di Massafra ‐ Azienda Sanitaria Locale di Taranto); Olga Lamacchia (Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia); Salvatore Arena (Ospedale Umberto I ‐ Azienda Sanitaria Provinciale di Siracusa); Antonino Di Benedetto (Azienda Ospedaliera Universitaria Policlinico G. Martino di Messina); Lucia Frittitta (Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi di Catania); Carla Giordano (Azienda Universitaria Policlinico Paolo Giaccone di Palermo); Salvatore Piro (Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi di Catania); Manfredi Rizzo, Roberta Chianetta and Carlo Mannina (Azienda Universitaria Policlinico Paolo Giaccone di Palermo); Roberto Anichini (Ospedale San Jacopo di Pistoia ‐ Azienda USL Toscana Centro); Giuseppe Penno (Azienda Ospedaliero Universitaria Pisana); Anna Solini (Azienda Ospedaliera Universitaria Pisana); Bruno Fattor (Comprensorio Sanitario di Bolzano ‐ Azienda Sanitaria della Provincia Autonoma di Bolzano); Enzo Bonora and Massimo Cigolini (Azienda Ospedaliero Universitaria Integrata di Verona); Annunziata Lapolla and Nino Cristiano Chilelli (Complesso Socio Sanitario Ai Colli ‐ Azienda ULSS n.6 Euganea); Maurizio Poli (Ospedale Girolamo Fracastoro di San Bonifacio ‐ Azienda ULSS n.9 Scaligera); Natalino Simioni and Vera Frison (Ospedale di Cittadella ‐ Azienda ULSS n.6 Euganea); Carmela Vinci (Azienda ULSS n.4 Veneto Orientale).
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